Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
Epistemonikos ID: ab1b8e74dafcef6b20f49c6c57abf91ea8bdce29
First added on: Mar 01, 2025